Miso Park, Da-Sol Kuen, Jaewoo Park, Munkyung Choi, Yeonji Kim, Eun Chae Roh, Yong June Choi, Yoon Gyoon Kim, Yeonseok Chung, Sung Yun Cho, Keon Wook Kang
BACKGROUND: Immunological contexture differs across malignancies, and understanding it in the tumor microenvironment (TME) is essential for development of new anticancer agents in order to achieve synergistic effects with anti-programmed cell death protein-1 (PD-1) therapy. TYRO3, AXL, and MERTK receptors are bi-expressed in both cancer and immune cells, and thus emerge as promising targets for therapeutic intervention. Whereas AXL and MERTK have been extensively studied, the role of TYRO3, in the TME, is still undetermined...
January 2023: Journal for Immunotherapy of Cancer